603087 甘李药业
已收盘 03-04 15:00:00
资讯
新帖
简况
甘李药业（603087）披露GLR2037片获临床试验批准通知书，3月2日股价下跌2.24%
证券之星 · 03-02 22:38
甘李药业（603087）披露GLR2037片获临床试验批准通知书，3月2日股价下跌2.24%
甘李药业最新公告：获得GLR2037片药物临床试验批准通知书
证券之星 · 03-02 17:41
甘李药业最新公告：获得GLR2037片药物临床试验批准通知书
每周股票复盘：甘李药业（603087）两款胰岛素获欧盟积极意见
证券之星 · 03-01
每周股票复盘：甘李药业（603087）两款胰岛素获欧盟积极意见
甘李药业最新公告：赖脯胰岛素注射液及门冬胰岛素注射液上市许可申请获欧盟CHMP积极意见
证券之星 · 02-26
甘李药业最新公告：赖脯胰岛素注射液及门冬胰岛素注射液上市许可申请获欧盟CHMP积极意见
甘李药业（603087）披露关于变更保荐代表人的公告，2月24日股价上涨1.85%
证券之星 · 02-24
甘李药业（603087）披露关于变更保荐代表人的公告，2月24日股价上涨1.85%
甘李药业新提交“未公开”等2件商标注册申请
证券之星 · 02-15
甘李药业新提交“未公开”等2件商标注册申请
甘李药业新提交“未公开”等9件商标注册申请
证券之星 · 02-05
甘李药业新提交“未公开”等9件商标注册申请
每周股票复盘：甘李药业（603087）2025年净利预增78.96%至95.23%
证券之星 · 01-25
每周股票复盘：甘李药业（603087）2025年净利预增78.96%至95.23%
甘李药业公布国际专利申请：“一种雌激素受体蛋白降解靶向嵌合体化合物及其应用”
证券之星 · 01-24
甘李药业公布国际专利申请：“一种雌激素受体蛋白降解靶向嵌合体化合物及其应用”
甘李药业最新公告：2025年净利同比预增78.96%-95.23%
证券之星 · 01-21
甘李药业最新公告：2025年净利同比预增78.96%-95.23%
每周股票复盘：甘李药业（603087）甘精胰岛素获欧盟上市许可
证券之星 · 01-18
每周股票复盘：甘李药业（603087）甘精胰岛素获欧盟上市许可
甘李药业(603087.SH)：甘精胰岛素注射液及其预填充注射笔获得埃塞俄比亚药品注册批件
智通财经 · 01-15
甘李药业(603087.SH)：甘精胰岛素注射液及其预填充注射笔获得埃塞俄比亚药品注册批件
甘李药业最新公告：公司甘精胰岛素注射液获得欧盟委员会上市许可
证券之星 · 01-14
甘李药业最新公告：公司甘精胰岛素注射液获得欧盟委员会上市许可
甘李药业（603087）披露使用闲置募集资金进行现金管理进展，1月13日股价上涨0.31%
证券之星 · 01-13
甘李药业（603087）披露使用闲置募集资金进行现金管理进展，1月13日股价上涨0.31%
每周股票复盘：甘李药业（603087）解聘财务负责人孙程
证券之星 · 01-02
每周股票复盘：甘李药业（603087）解聘财务负责人孙程
甘李药业（603087）公司公告解聘高级管理人员及指定人员代行财务负责人职责，12月31日股价上涨1.66%
证券之星 · 2025-12-31
甘李药业（603087）公司公告解聘高级管理人员及指定人员代行财务负责人职责，12月31日股价上涨1.66%
光鲜下的另一面，BD交易后股价不涨反跌成常态？专家：短期热度降低不是坏事
时代周报 · 2025-12-25
光鲜下的另一面，BD交易后股价不涨反跌成常态？专家：短期热度降低不是坏事
长城国瑞证券：首次覆盖甘李药业给予买入评级
证券之星 · 2025-12-12
长城国瑞证券：首次覆盖甘李药业给予买入评级
全国药品流通市场销售规模略有增长；大宗中药材降价
21世纪经济报道 · 2025-12-09
全国药品流通市场销售规模略有增长；大宗中药材降价
甘李药业最新公告：子公司收到GLR1044注射液药物临床试验批准通知书
证券之星 · 2025-12-08
甘李药业最新公告：子公司收到GLR1044注射液药物临床试验批准通知书
加载更多
公司概况
公司名称：
甘李药业股份有限公司
所属行业：
医药制造业
上市日期：
2020-06-29
主营业务：
甘李药业股份有限公司的主营业务是胰岛素类似物原料药及注射剂研发、生产和销售。公司的主要产品是生物制品(原料药及制剂产品)、化药、医疗器械及其他、特许权服务。2025年5月，公司被纳入标普全球《可持续发展年鉴（中国版）2025》，同时被授予“行业最佳进步企业”的荣誉称号。
发行价格：
63.32
{"stockData":{"symbol":"603087","market":"SH","secType":"STK","nameCN":"甘李药业","latestPrice":62.06,"timestamp":1772607601000,"preClose":62.64,"halted":0,"volume":5719832,"delay":0,"changeRate":-0.0093,"floatShares":558000000,"shares":597000000,"eps":1.5499,"marketStatus":"已收盘","change":-0.58,"latestTime":"03-04 15:00:00","open":62,"high":62.88,"low":61.54,"amount":356000000,"amplitude":0.0214,"askPrice":62.06,"askSize":16,"bidPrice":62.05,"bidSize":39,"shortable":0,"etf":0,"ttmEps":1.5499,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1772674200000},"marketStatusCode":5,"adr":0,"adjPreClose":62.64,"symbolType":"stock","openAndCloseTimeList":[[1772587800000,1772595000000],[1772600400000,1772607600000]],"highLimit":68.9,"lowLimit":56.38,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":597304969,"isCdr":false,"pbRate":3.29,"roa":"--","peRate":40.041293,"roe":"7.21%","epsLYR":1.04,"committee":-0.023041,"marketValue":37069000000,"turnoverRate":0.0103,"status":1,"floatMarketCap":34621000000},"requestUrl":"/m/hq/s/603087","defaultTab":"news","newsList":[{"id":"2616355649","title":"甘李药业（603087）披露GLR2037片获临床试验批准通知书，3月2日股价下跌2.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616355649","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616355649?lang=zh_cn&edition=full","pubTime":"2026-03-02 22:38","pubTimestamp":1772462302,"startTime":"0","endTime":"0","summary":"截至2026年3月2日收盘，甘李药业报收于64.49元，较前一交易日下跌2.24%，最新总市值为385.2亿元。该股当日开盘65.0元，最高65.64元，最低63.83元，成交额达4.27亿元，换手率为1.19%。近日，甘李药业股份有限公司收到国家药品监督管理局下发的《药物临床试验批准通知书》，同意公司自主研发的GLR2037片开展晚期前列腺癌的临床试验。公司已累计投入研发费用5,805.47万元。后续将按要求开展临床试验，待试验成功后申报生产。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030200039974.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603087"],"gpt_icon":0},{"id":"2616805503","title":"甘李药业最新公告：获得GLR2037片药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2616805503","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616805503?lang=zh_cn&edition=full","pubTime":"2026-03-02 17:41","pubTimestamp":1772444462,"startTime":"0","endTime":"0","summary":"甘李药业公告称，公司近日收到国家药品监督管理局下发的关于在研药品GLR2037片的《药物临床试验批准通知书》，同意开展晚期前列腺癌的临床试验。前列腺癌是男性泌尿生殖道肿瘤中最常见的肿瘤之一，发病率在全球男性恶性肿瘤中排名第2位。截至2025年9月30日，该项目累计投入研发费用5805.47万元人民币。由于医药产品研发具有不确定性，公司将积极推进该项目并及时履行信息披露义务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030200026497.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603087","BK0239"],"gpt_icon":0},{"id":"2616434558","title":"每周股票复盘：甘李药业（603087）两款胰岛素获欧盟积极意见","url":"https://stock-news.laohu8.com/highlight/detail?id=2616434558","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616434558?lang=zh_cn&edition=full","pubTime":"2026-03-01 02:11","pubTimestamp":1772302271,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，甘李药业报收于65.97元，较上周的64.99元上涨1.51%。本周，甘李药业2月26日盘中最高价报67.16元。本周关注点公司公告汇总：赖脯胰岛素和门冬胰岛素注射液获欧盟CHMP积极意见。）上市许可申请获得欧盟CHMP积极意见的公告甘李药业股份有限公司及其欧洲全资子公司甘李药业欧洲有限责任公司收到欧洲药品管理局通知，赖脯胰岛素注射液和门冬胰岛素注射液获得EMA人用药品委员会积极意见。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100000701.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["FSXEmain","BK0239","603087","FESXmain"],"gpt_icon":0},{"id":"2614101663","title":"甘李药业最新公告：赖脯胰岛素注射液及门冬胰岛素注射液上市许可申请获欧盟CHMP积极意见","url":"https://stock-news.laohu8.com/highlight/detail?id=2614101663","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614101663?lang=zh_cn&edition=full","pubTime":"2026-02-26 17:13","pubTimestamp":1772097191,"startTime":"0","endTime":"0","summary":"甘李药业公告称，公司及其欧洲全资子公司甘李药业欧洲有限责任公司收到欧洲药品管理局通知，赖脯胰岛素注射液、门冬胰岛素注射液获得CHMP积极意见。CHMP建议欧盟委员会批准这两款药物作为生物类似药上市，用于治疗糖尿病。此次获得CHMP积极意见标志着公司产品在欧洲市场上市进程取得突破性进展，但能否获得欧盟委员会批准及获批时间仍存在不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022600025772.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603087","FSXEmain","FESXmain"],"gpt_icon":0},{"id":"2613797510","title":"甘李药业（603087）披露关于变更保荐代表人的公告，2月24日股价上涨1.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613797510","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613797510?lang=zh_cn&edition=full","pubTime":"2026-02-24 18:34","pubTimestamp":1771929253,"startTime":"0","endTime":"0","summary":"截至2026年2月24日收盘，甘李药业报收于66.19元，较前一交易日上涨1.85%，最新总市值为395.36亿元。近日，甘李药业股份有限公司披露《关于变更保荐代表人的公告》。本次变更后，持续督导保荐代表人为赵陆胤女士和邵才捷女士，持续督导期至中国证监会和上交所规定结束为止。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022400037539.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603087"],"gpt_icon":0},{"id":"2611914188","title":"甘李药业新提交“未公开”等2件商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2611914188","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611914188?lang=zh_cn&edition=full","pubTime":"2026-02-15 06:09","pubTimestamp":1771106958,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示，近日甘李药业股份有限公司新提交“未公开”等2件商标注册申请。商标申请详情如下：今年以来甘李药业股份有限公司新申请注册商标13件，截止目前公司共持有注册商标368件，另有66件商标尚在注册申请中。通过天眼查大数据分析，甘李药业股份有限公司共对外投资了7家企业，参与招投标项目2450次；财产线索方面有商标信息314条，专利信息119条，著作权信息4条；此外企业还拥有行政许可453个。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021500000917.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603087"],"gpt_icon":0},{"id":"2609311829","title":"甘李药业新提交“未公开”等9件商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2609311829","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609311829?lang=zh_cn&edition=full","pubTime":"2026-02-05 06:29","pubTimestamp":1770244152,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示，近日甘李药业股份有限公司新提交“未公开”等9件商标注册申请。商标申请详情如下：今年以来甘李药业股份有限公司新申请注册商标9件，截止目前公司共持有注册商标368件，另有62件商标尚在注册申请中。通过天眼查大数据分析，甘李药业股份有限公司共对外投资了6家企业，参与招投标项目2447次；财产线索方面有商标信息300条，专利信息118条，著作权信息4条；此外企业还拥有行政许可453个。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020500003306.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603087"],"gpt_icon":0},{"id":"2606823241","title":"每周股票复盘：甘李药业（603087）2025年净利预增78.96%至95.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606823241","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606823241?lang=zh_cn&edition=full","pubTime":"2026-01-25 02:57","pubTimestamp":1769281029,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘，甘李药业报收于72.83元，较上周的71.82元上涨1.41%。本周关注点业绩披露要点：甘李药业预计2025年净利同比增长78.96%至95.23%。业绩披露要点甘李药业发布业绩预告，预计2025年全年归属净利润盈利11亿元至12亿元，同比增长78.96%至95.23%；扣非后净利润盈利7亿元至8亿元，同比增长62.63%至85.86%。控股股东甘忠如及其控制的旭特宏达合计持股占公司总股本39.80%，累计质押股份占其持股总数9.55%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012500000975.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603087"],"gpt_icon":0},{"id":"2605817372","title":"甘李药业公布国际专利申请：“一种雌激素受体蛋白降解靶向嵌合体化合物及其应用”","url":"https://stock-news.laohu8.com/highlight/detail?id=2605817372","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605817372?lang=zh_cn&edition=full","pubTime":"2026-01-24 08:50","pubTimestamp":1769215839,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示甘李药业（603087）公布了一项国际专利申请，专利名为“一种雌激素受体蛋白降解靶向嵌合体化合物及其应用”，专利申请号为PCT/CN2025/102221，国际公布日为2026年1月15日。专利详情如下：图片来源：世界知识产权组织（WIPO）今年以来甘李药业已公布的国际专利申请2个。结合公司2025年中报财务数据，2025上半年公司在研发方面投入了2.65亿元，同比减0.73%。数据来源：企查查以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012400011725.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603087","BK0239"],"gpt_icon":0},{"id":"2605012170","title":"甘李药业最新公告：2025年净利同比预增78.96%-95.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605012170","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605012170?lang=zh_cn&edition=full","pubTime":"2026-01-21 17:50","pubTimestamp":1768989051,"startTime":"0","endTime":"0","summary":"甘李药业(603087.SH)发布2025年度业绩预告，预计归属于上市公司股东的净利润为11.00亿元到12.00亿元，与上年同期相比增加78.96%到95.23%。报告期内，公司国内外收入增长，胰岛素制剂产品销量与销售额大幅上升，国际化战略推进取得成效，同时因转让甘甘江苏55%股权获得投资收益，带动净利润增长。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012100030047.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603087"],"gpt_icon":0},{"id":"2604892846","title":"每周股票复盘：甘李药业（603087）甘精胰岛素获欧盟上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2604892846","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604892846?lang=zh_cn&edition=full","pubTime":"2026-01-18 01:42","pubTimestamp":1768671732,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，甘李药业报收于71.82元，较上周的71.0元上涨1.15%。本周关注点公司公告汇总：甘精胰岛素注射液获得欧盟委员会上市许可，适应症为治疗成人、青少年和2岁及以上儿童糖尿病。甘李药业股份有限公司近日收到埃塞俄比亚国家食品药品监督管理局核准签发的甘精胰岛素注射液及预填充注射笔注册批件，批件号分别为11865/13208/NMR/2025和11864/13210/NMR/2025。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011800000279.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603087","BK0239","FSXEmain","FESXmain"],"gpt_icon":0},{"id":"2603600145","title":"甘李药业(603087.SH)：甘精胰岛素注射液及其预填充注射笔获得埃塞俄比亚药品注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2603600145","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603600145?lang=zh_cn&edition=full","pubTime":"2026-01-15 21:04","pubTimestamp":1768482250,"startTime":"0","endTime":"0","summary":"智通财经APP讯，甘李药业(603087.SH)发布公告，近日，公司收到埃塞俄比亚国家食品药品监督管理局核准签发的甘精胰岛素注射液及甘精胰岛素注射液预填充注射笔注册批件(批件号：11865/13208/NMR/2025、11864/13210/NMR/2025)。甘精胰岛素为基础长效胰岛素，每天皮下注射一次，降糖作用时间持续24小时。其具有作用时间长、血药浓度平稳无峰和平稳控糖的特点。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1393507.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"甘李药业(603087.SH)：甘精胰岛素注射液及其预填充注射笔获得埃塞俄比亚药品注册批件","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","603087"],"gpt_icon":0},{"id":"2603698951","title":"甘李药业最新公告：公司甘精胰岛素注射液获得欧盟委员会上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2603698951","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603698951?lang=zh_cn&edition=full","pubTime":"2026-01-14 15:41","pubTimestamp":1768376490,"startTime":"0","endTime":"0","summary":"甘李药业(603087.SH)公告称，公司产品甘精胰岛素注射液（商品名：Ondibta）获得在欧盟、冰岛、列支敦士登和挪威的上市许可，适用于治疗成人、青少年和2岁及以上糖尿病患者。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011400020790.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603087","BK0239"],"gpt_icon":0},{"id":"2603468023","title":"甘李药业（603087）披露使用闲置募集资金进行现金管理进展，1月13日股价上涨0.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603468023","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603468023?lang=zh_cn&edition=full","pubTime":"2026-01-13 22:20","pubTimestamp":1768314033,"startTime":"0","endTime":"0","summary":"截至2026年1月13日收盘，甘李药业报收于70.1元，较前一交易日上涨0.31%，最新总市值为418.71亿元。该股当日开盘69.72元，最高71.83元，最低69.7元，成交额达8.06亿元，换手率为2.04%。公司近日发布公告称，甘李药业股份有限公司使用闲置募集资金25,000万元购买中国银行北京通州分行的人民币结构性存款，产品期限181天，收益类型为保本浮动收益型，预计年化收益率0.4%或2.2%，资金来源为暂时闲置的募集资金。此前到期的20,000万元结构性存款已赎回，获得收益211.25万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011300042310.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603087"],"gpt_icon":0},{"id":"2600843035","title":"每周股票复盘：甘李药业（603087）解聘财务负责人孙程","url":"https://stock-news.laohu8.com/highlight/detail?id=2600843035","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600843035?lang=zh_cn&edition=full","pubTime":"2026-01-02 01:21","pubTimestamp":1767288068,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，甘李药业报收于68.29元，较上周的67.88元上涨0.6%。本周，甘李药业12月26日盘中最高价报68.5元。公司公告汇总甘李药业股份有限公司因业务调整，解聘孙程的财务负责人、副总经理职务，其不再担任公司任何职务。孙程持有已解除限售的限制性股票18.22万股，已获授但未解除限售的32.8万股将由公司回购注销。同时，会议审议通过指定周丽女士在董事会正式聘任财务负责人之前代行财务负责人职责的议案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010200000209.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603087","BK0239"],"gpt_icon":0},{"id":"2595772227","title":"甘李药业（603087）公司公告解聘高级管理人员及指定人员代行财务负责人职责，12月31日股价上涨1.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595772227","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595772227?lang=zh_cn&edition=full","pubTime":"2025-12-31 22:04","pubTimestamp":1767189861,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘，甘李药业报收于68.07元，较前一交易日上涨1.66%，最新总市值为406.59亿元。近日，甘李药业发布公告称，因业务调整，公司解聘孙程的财务负责人、副总经理职务，其离职后不再担任公司任何职务。公告显示，孙程持有已解除限售的限制性股票18.22万股，已获授但未解除限售的32.8万股将由公司回购注销。为保障财务工作平稳运行，董事会指定周丽在董事会正式聘任新的财务负责人之前代行财务负责人职责。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100044342.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603087","BK0239"],"gpt_icon":0},{"id":"2594287939","title":"光鲜下的另一面，BD交易后股价不涨反跌成常态？专家：短期热度降低不是坏事","url":"https://stock-news.laohu8.com/highlight/detail?id=2594287939","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594287939?lang=zh_cn&edition=full","pubTime":"2025-12-25 14:21","pubTimestamp":1766643688,"startTime":"0","endTime":"0","summary":"今年创新药企业频繁宣布BD交易，但从三季度以来，原本利好的消息却不被二级市场买账。最近一周，BD交易再掀一个小高潮。12月22日，先声药业（02096.HK）宣布其附属公司江苏再明与Ipsen于12月19日签订独家授权许可协议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512253601825588.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","BK0239","LU1064131003.USD","BK0060","LU2097828631.EUR","LU2097828805.USD","LU2148510915.USD","BK1593","BK0183","01801","02509","LU1146622755.USD","06978","LU2097828474.EUR","600276","LU0405327494.USD","000661","LU2495084118.USD","LU1997245177.USD","LU1328615791.USD","03692","LU2580892862.HKD","BK0188","688428","LU1064130708.USD","02096","BK1161","688062","LU1969619763.USD","01167","LU1997244956.HKD","LU1781817850.SGD","BK0196","LU0405327148.USD","LU1997245094.SGD","688331","LU2097828714.EUR","LU2097828557.USD","603087","LU2488822045.USD","002755","BK1589","BK0057","09995","01530","BK0028","688336","BK0012","02142","LU0502904849.HKD"],"gpt_icon":0},{"id":"2590503214","title":"长城国瑞证券：首次覆盖甘李药业给予买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2590503214","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590503214?lang=zh_cn&edition=full","pubTime":"2025-12-12 19:38","pubTimestamp":1765539494,"startTime":"0","endTime":"0","summary":"长城国瑞证券胡晨曦近期对甘李药业进行研究并发布了研究报告《两轮集采实现蜕变，创新+国际化驱动第二增长曲线》，首次覆盖甘李药业给予买入评级。两轮胰岛素集采中，甘李药业实现从降价换量到量价齐升的转变。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121200034706.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","603087"],"gpt_icon":0},{"id":"2590362722","title":"全国药品流通市场销售规模略有增长；大宗中药材降价","url":"https://stock-news.laohu8.com/highlight/detail?id=2590362722","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590362722?lang=zh_cn&edition=full","pubTime":"2025-12-09 08:16","pubTimestamp":1765239401,"startTime":"0","endTime":"0","summary":"政策动向全国药品流通市场销售规模略有增长12月8日，商务部发布《2024年药品流通行业运行统计分析报告》（以下简称《报告》），发布了2024年我国药品流通行业规模、行业效益、医药物流配送、医药电商、上市公司等数据，分析了行业运行特点，并对未来发展趋势进行了展望。《报告》显示，2024年，全国药品流通市场销售规模略有增长。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512093585873562.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512093585873562.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0188","600222","603087","BK0239"],"gpt_icon":0},{"id":"2589343333","title":"甘李药业最新公告：子公司收到GLR1044注射液药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2589343333","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589343333?lang=zh_cn&edition=full","pubTime":"2025-12-08 18:40","pubTimestamp":1765190441,"startTime":"0","endTime":"0","summary":"甘李药业(603087.SH)公告称，公司全资子公司甘李药业山东有限公司收到国家药品监督管理局下发的关于在研药品GLR1044注射液的《药物临床试验批准通知书》。GLR1044注射液为达必妥（度普利尤单抗）的生物类似药，用于治疗外用处方药控制不佳或不建议使用外用处方药的成人中重度特应性皮炎。截至2025年9月30日，甘李药业在GLR1044项目中累计投入研发费用6572.45万元人民币。由于医药产品研发周期长、环节多，存在不确定性，敬请广大投资者谨慎决策，注意投资风险。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120800024577.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603087","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1772624835205,"stockEarnings":[{"period":"1week","weight":-0.0536},{"period":"1month","weight":-0.0736},{"period":"3month","weight":0.0111},{"period":"6month","weight":-0.1247},{"period":"1year","weight":0.3988},{"period":"ytd","weight":-0.0798}],"compareEarnings":[{"period":"1week","weight":0.0013},{"period":"1month","weight":0.0011},{"period":"3month","weight":0.0631},{"period":"6month","weight":0.0947},{"period":"1year","weight":0.2429},{"period":"ytd","weight":0.0388}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"甘李药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"94714人(较上一季度增加22.53%)","perCapita":"5889股","listingDate":"2020-06-29","address":"北京市通州区漷县镇南凤西一路8号","registeredCapital":"59730万元","survey":" 甘李药业股份有限公司的主营业务是胰岛素类似物原料药及注射剂研发、生产和销售。公司的主要产品是生物制品(原料药及制剂产品)、化药、医疗器械及其他、特许权服务。2025年5月，公司被纳入标普全球《可持续发展年鉴（中国版）2025》，同时被授予“行业最佳进步企业”的荣誉称号。","listedPrice":63.32},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"甘李药业(603087)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供甘李药业(603087)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"甘李药业,603087,甘李药业股票,甘李药业股票老虎,甘李药业股票老虎国际,甘李药业行情,甘李药业股票行情,甘李药业股价,甘李药业股市,甘李药业股票价格,甘李药业股票交易,甘李药业股票购买,甘李药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"甘李药业(603087)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供甘李药业(603087)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}